Literature DB >> 3917812

Circadian changes in anticoagulant effect of heparin infused at a constant rate.

H A Decousus, M Croze, F A Levi, J G Jaubert, B M Perpoint, J F De Bonadona, A Reinberg, P M Queneau.   

Abstract

Six patients with venous thromboembolism were treated with heparin, administered intravenously by a constant infusion pump. The initial daily dose of heparin was adjusted to keep the activated partial thromboplastin time, sampled at 0800, between 1.5 and 2.5 times the control level. Once that level was obtained, this dose was kept constant. Anticoagulation was thereafter measured, every four hours for 48 hours, by activated partial thromboplastin time, thrombin time, and coagulation factor Xa inhibition assay. The results of all three coagulation tests showed a circadian variation in the six patients. Maximum values were achieved at night and minimum values in the morning. These circadian variations were reproduced for two consecutive days. Differences between night and morning values reached almost 50% for activated partial thromboplastin time, 60% for thrombin time, and 40% for factor Xa inhibition assay. This circadian variation resulted from two rhythms, a circadian rhythm lasting 24 hours and an ultradian rhythm lasting 12 hours, which were detected by cosinor analysis for each coagulation test (p less than 0.01). A circadian rhythm was detected individually in most of the patients for each coagulation test (p less than 0.05). All patients had a nocturnal peak in activated partial thromboplastin time on both days. In four patients this peak exceeded the upper desired limit of activated partial thromboplastin time. These rhythms should be taken into account when evaluating the dosage of heparin to be administered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917812      PMCID: PMC1417335          DOI: 10.1136/bmj.290.6465.341

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

Review 1.  Heparin: new concepts relevant to clinical use.

Authors:  S Wessler; S N Gitel
Journal:  Blood       Date:  1979-04       Impact factor: 22.113

2.  Plasma heparin: a unique, practical, submicrogram-sensitive assay.

Authors:  E T Yin; S Wessler; J V Butler
Journal:  J Lab Clin Med       Date:  1973-02

3.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

4.  Methods for cosinor-rhythmometry.

Authors:  W Nelson; Y L Tong; J K Lee; F Halberg
Journal:  Chronobiologia       Date:  1979 Oct-Dec

5.  Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time.

Authors:  J T Brandt; D A Triplett
Journal:  Am J Clin Pathol       Date:  1981-10       Impact factor: 2.493

6.  Clinical chronopharmacology.

Authors:  A Reinberg; M Smolensky; F Lévi
Journal:  Biomedicine       Date:  1981-12

7.  [Controlled heparin therapy].

Authors:  C Raby
Journal:  Presse Med       Date:  1967-06-17       Impact factor: 1.228

8.  Heparin therapy in venous thromboembolism.

Authors:  J E Wilson; L J Bynum; R W Parkey
Journal:  Am J Med       Date:  1981-04       Impact factor: 4.965

9.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; B Djazaeri; J Fok; M Fletcher; M F Scully; J Westwick
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06

10.  Haemorrhagic complications of heparin therapy.

Authors:  M J Mant; B D O'Brien; K L Thong; G W Hammond; R V Birtwhistle; M G Grace
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

View more
  15 in total

1.  Circadian activity rhythms and mortality: the study of osteoporotic fractures.

Authors:  Gregory J Tranah; Terri Blackwell; Sonia Ancoli-Israel; Misti L Paudel; Kristine E Ensrud; Jane A Cauley; Susan Redline; Teresa A Hillier; Steven R Cummings; Katie L Stone
Journal:  J Am Geriatr Soc       Date:  2010-01-26       Impact factor: 5.562

Review 2.  Chronotherapeutics for cardiovascular disease.

Authors:  Y A Anwar; W B White
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 4.  Susceptibility to adverse drug reactions.

Authors:  Robin Ferner; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

5.  Guidelines to control heparin treatment.

Authors:  A G Fennerty; S Renowden; N Scolding; D P Bentley; I A Campbell; P A Routledge
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

Review 6.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

7.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 8.  Anticoagulants in venous thromboembolism.

Authors:  A Fennerty; I A Campbell; P A Routledge
Journal:  BMJ       Date:  1988-11-19

Review 9.  Circadian rhythms: from basic mechanisms to the intensive care unit.

Authors:  Ming-Cheng Chan; Peter M Spieth; Kieran Quinn; Matteo Parotto; Haibo Zhang; Arthur S Slutsky
Journal:  Crit Care Med       Date:  2012-01       Impact factor: 7.598

Review 10.  Chronobiology in mammalian health.

Authors:  Zhihua Liu; Guiyan Chu
Journal:  Mol Biol Rep       Date:  2012-12-06       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.